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Abstract
Upon colonization, Staphylococcus aureus must withstand the actions of many host defense
mechanisms, including the unsaturated free fatty acids (uFFAs) secreted in sebum. Linoleic
acid, a representative uFFA, is toxic to S. aureus at concentrations ≥50 µM; however, we
selected for mutants capable of growing at elevated concentrations of linoleic acid. Five
mutants had single nucleotide polymorphisms (SNPs) in the cvfA gene encoding an RNase
that is a component of the RNA degradosome, and expression of the SNP-containing cvfA
genes from a plasmid engendered S. aureus with high level resistance to linoleic acid. The
SNPs were located within a region of the protein with unknown function, between the RNAbinding and catalytic domains. We have confirmed that at least one of the SNPs does not
impact CvfA catalytic activity. Further research is required to determine the mechanism by
which SNPs in cvfA confer increased resistance to uFFAs.
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Chapter 1

1

Literature Review

Staphylococcus aureus is a common human pathogen that poses a significant burden to
health care systems worldwide. It is one of the ESKAPE superbugs, a group of
pathogens encompassing Enterococcus faecium, S. aureus, Klebsiella pneumonia,
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species (1).
These pathogens are responsible for a majority of nosocomial infections and are capable
of ‘escaping’ the actions of antibiotics. S. aureus employs a multitude of virulence and
colonization factors that contribute to its success in causing infections, in part by helping
withstand attack by the human immune system. The antibacterial free fatty acids on skin
and in nasal secretions are among our first lines of defense against S. aureus and are
known to dramatically increase in concentration during abscess formation (2). Further
characterization of the mechanisms employed by S. aureus to overcome this component
of innate immunity will increase our understanding of the first stages of infection. This
will provide insight into the role of fatty acids in controlling infection, and is the subject
of this thesis work.

1.1 Staphylococci and Staphylococcus aureus
The staphylococci are gram-positive firmicutes characterized by their spherical
morphology and tendency to grow in grape-like clusters. They are facultative anaerobes,
highly halotolerant with growth able to occur in >2M NaCl, and are catalase-positive,
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allowing them to be distinguished from the catalase-negative streptococci (3). The
majority of S. aureus strains are coagulase-positive while many other staphylococcal
species are coagulase-negative. S. aureus is a common cause of infectious diseases and
coagulase aids in prevention of host cell attack by acting within the blood to convert
fibrinogen to fibrin which then adheres to S. aureus cells, shielding them from the host
immune system (3). The coagulase-negative staphylococci had previously been regarded
as non-pathogenic, or associated with low pathogenicity, however this view has since
changed and many coagulase-negative staphylococci are now known to be responsible
for causing opportunistic invasive infections (4).
There are over 45 staphylococcal species (4) and while many are able to colonize
humans, arguably the most well-known are S. epidermidis and S. aureus. S. epidermidis
is non-pigmented and less commonly associated with infections whereas S. aureus
produces a golden colour and is a leading cause of both hospital- and communityacquired infections. The golden pigment after which S. aureus was named is due to the
biosynthesis of staphyloxanthin, an orange carotenoid (5). A major role for
staphyloxanthin is that of an antioxidant, defending S. aureus against reactive oxygen
species thereby increasing its fitness and virulence (6, 7). Aside from staphyloxanthin,
the staphylococci are known to harbour a diverse arsenal of virulence factors, further
discussed in section 1.1.2, that aid in their remarkable success as pathogens.

1.1.1

Clinical relevance

S. aureus, both a commensal and a dangerous pathogen, presents a significant healthcare
burden as it is the most common cause of infective endocarditis in industrialized nations
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(8) and lower respiratory tract and surgical site infections (9). It is also the second most
common cause of nosocomial bacteremia (10), cardiovascular infections, and pneumonia
in the United States (9). However, it is also a significant cause of many other infections,
such as skin and soft tissue infections, osteomyelitis, and cellulitis. Interestingly, the
most common cause of nosocomial bacteremia was the coagulase-negative staphylococci
and therefore, if all staphylococci are considered as a single group, they were found to be
responsible for 51% of hospital-acquired bloodstream infections (10).
While the coagulase-negative staphylococci are becoming increasingly more common
causes of infections, S. aureus reigns supreme in its prevalence and ability to cause
infections. High colonization rates of S. aureus are in part responsible for its success as a
pathogen, as individuals who are colonized serve as reservoirs for S. aureus transmission
within the community. The most common bodily site colonized by S. aureus is the
anterior nares, but it also regularly colonizes the skin, perineum, axillae, and pharynx
(11). It is considered an opportunistic pathogen as many individuals are
asymptomatically colonized – approximately 20% of the population is persistently
colonized, 30% are transiently colonized, and 50% are non-carriers (12). Although
individuals that are colonized have a higher likelihood of infection, they also have a
better prognosis if they do contract an infection (13). Specifically, carriers were found to
have a 3-fold greater risk of nosocomial S. aureus bacteremia over non-carriers; however,
mortality was higher in the non-carriers at 46% compared to the carriers at 18% (13).
Additionally, colonized individuals are more likely to become infected with their resident
S. aureus strain as opposed to a foreign strain (14).
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Unfortunately, infections caused by S. aureus are not simple to treat as this species has
acquired resistance to many antibiotics. It was not long after the introduction of
methicillin in the clinic that methicillin resistant S. aureus (MRSA) was first identified in
the United Kingdom in 1961 (15). This was followed by relatively infrequent outbreaks
of MRSA in the UK and the first hospital outbreak in the United States in Boston, MA in
1968 (16). In US hospitals in 2003, the economic burden of S. aureus infections was
$14.5 billion while the overall mortality rate for inpatient stays was 5.6% (17). However,
for S. aureus bacteremia cases, the mortality rate was found to be as high as 42% when
caused by MRSA and 28% for methicillin-sensitive S. aureus (MSSA) (18). These
devastating statistics highlight the significant impact of S. aureus infections on society
and outline the need for additional and improved therapeutics.
While the hospital outbreaks are concerning, there has been another source of serious
concern developing over the past couple decades regarding the emergence of communityacquired MRSA (CA-MRSA). CA-MRSA infections are those obtained outside of the
healthcare setting in individuals lacking classic risk factors. The first reported case of
CA-MRSA was in 1980 in Detroit, Michigan (19) but it wasn’t until the mid-1990s that a
significant number of reports on the subject began to surface (20–24). Since then, cases
of CA-MRSA have risen dramatically. For example, one study based out of an Atlanta,
Georgia hospital and outpatient clinics found CA-MRSA strains to be responsible for
87% of MRSA infections (25). It is important to note, however, that the line between
CA-MRSA and healthcare-associated MRSA (HA-MRSA) strains has blurred and both
strains can be found in the community and in hospital settings (26, 27).
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Traditionally, HA-MRSA strains were considered to be resistant to a greater number of
antibiotics than CA-MRSA strains, while the CA-MRSA strains generally have increased
virulence potential (28, 29). These differences led researchers to question the initial
assumption that CA-MRSA strains evolved from HA-MRSA strains and it was
determined that CA-MRSA was more likely to have arisen from MSSA strains that were
already circulating in the community (30–32). Although CA-MRSA strains have
historically been susceptible to non-β-lactam antibiotics, it is becoming increasingly
common for these strains to be resistant to other antibiotics, such as erythromycin and
clindamycin (33). Regardless, CA-MRSA strains are very successful pathogens that are
capable of causing serious and even fatal infections (20).

1.1.2

Virulence factor regulation and pathogenesis

The ability of S. aureus to cause severe and diverse infections is due in part to its large
arsenal of virulence factors. Three important regulators of virulence in this pathogen are
the agr (staphylococcal accessory gene regulator), sarA (staphylococcal accessory
regulator), and sae (S. aureus exoprotein expression) systems. Control of virulence is
complex and the regulons of many virulence regulators are interconnected, with overlap
in the factors whose expression they control. These global regulators are particularly
crucial in vivo where their activity allows for rapid adaptation to the changing
environments encountered by S. aureus, ensuring expression of appropriate factors that
allow for colonization and subsequent dissemination.
The agr quorum-sensing system is crucial for cell-cell signaling and regulation of
virulence factors throughout various growth stages (34). It is responsible for increasing
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the expression of exoproteins (e.g. toxins, exoenzymes) while decreasing the expression
of cell surface proteins (e.g. extracellular matrix adhesins and IgG binding proteins)
during the late-exponential and stationary growth phases (35). The agr system comprises
two transcripts, RNAII and RNAIII, that are divergently transcribed from the P2 and P3
promoters, respectively (36, 37). RNAII encodes 4 proteins that are responsible for the
quorum sensing functions of this system, AgrB, AgrD, AgrC, and AgrA. AgrB is a
membrane protein that serves to process AgrD into the autoinducing peptide (AIP) as
well as to translocate it into the extracellular environment during exponential phase.
AgrA and AgrC form a two-component sensing system whereby AgrC is the
transmembrane receptor for the AIP. Upon binding of the AIP to AgrC, AgrC undergoes
a conformational change, resulting in homodimerisation and autophosphorylation. This
phosphate is then transferred onto AgrA, a cytoplasmic protein, causing conformational
changes within AgrA that then allows it to bind the P2 and P3 promoters, resulting in
increased transcription of these operons and completing the positive feedback loop. The
RNAIII transcript is the effector of the agr system and also encodes hld, δ-hemolysin
(37). As the effector, RNAIII increases the transcription and/or translation (38) of
various secreted virulence factors such as toxic shock syndrome toxin-1 (TSST-1),
Panton-Valentine leukocidin (PVL) (39), and a variety of hemolysins and proteases (34,
40). It also decreases the expression of select surface-associated proteins, such as Protein
A and fibronectin-binding protein (41, 42).
In addition to the positive feedback mechanism mediated by AgrA, SarA activates
expression of the agr operon (43), and SarR acts to repress RNAII transcription (44).
The SarA protein family consists of DNA binding proteins that alter expression of
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virulence genes. The agr operon and SarA protein family are intricately entwined as agr
activation results in repression of sarS and sarT transcription, which activate protein A
and repress α-hemolysin, respectively (45, 46).
Another important virulence regulator is the saePQRS system, which is composed of four
genes transcribed from two promoters, producing a total of four transcripts (47, 48). The
T1 transcript is transcribed from the P1 promoter and includes all four genes. It is
processed by endonucleolytic cleavage by CvfA (RNase Y), producing the T2 transcript
which no longer contains saeP (49). The T3 transcript is transcribed from the P3
promoter and contains saeR and saeS, and the T4 transcript is monocistronic, containing
only saeP. SaeS and SaeR form a two-component system consisting of a sensor histidine
kinase and response regulator, respectively. The sensor, SaeS, is membrane-bound and
upon sensing an environmental signal, it autophosphorylates and subsequently transfers
this phosphate to the regulator, SaeR (50). It has been suggested that SaeS monitors
disruptions to the membrane, but this has not been conclusively shown (51).
Phosphorylation of SaeR results in a conformational change that allows it to bind DNA,
influencing the expression of numerous targets including α-hemolysin, β-hemolysin,
coagulase, DNase, and extracellular protein A (47, 52). The role of SaeP and SaeQ has
only recently been elucidated and they have been shown to act in concert to turn off SaeS
by activating its phosphatase activity, resulting in the dephosphorylation of SaeR (53).
The virulence factors governed by these regulators are numerous and fundamental to the
pathogenesis of S. aureus infections. Virulence factors such as the MSCRAMMs
(microbial surface components recognizing adhesive matrix molecules) are important in
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order for S. aureus to establish colonization, and factors such as hemolysins, proteases,
and lipases are important for tissue invasion and destruction (54). There are also various
toxins responsible for specific diseases, such as toxic shock syndrome caused by TSST-1,
food poisoning caused by staphylococcal enterotoxins, and scalded skin syndrome caused
by exfoliative toxins. TSST-1 and the enterotoxins are superantigens which are
exoproteins that bind to MHC class II molecules regardless of antigen specificity and link
them to T-cell receptors. This action results in a substantial increase in the number of
activated T cells and causes the release of massive amounts of cytokines, which are
responsible for the symptoms associated with the disease. The exfoliative toxins cleave
desmoglein-1, a human protein involved in keratinocyte cell-cell adhesion, thereby
disrupting the integrity of the skin and causing the blistering that is characteristic of
scalded skin syndrome (55). Evidently, S. aureus is very well-equipped in terms of
virulence factors producing disease; however, another important factor in the
pathogenesis of S. aureus infections is the ability of this pathogen to evade detection and
destruction by the host’s immune system.

1.1.3

Immune evasion

Throughout the course of establishing an infection, a bacterium must survive or avoid
assault by the host’s immune system and this is a skill that S. aureus has mastered. S.
aureus evades detection by utilizing proteins such as protein A and clumping factor A.
Protein A is a well characterized wall-anchored protein that binds to the Fc portion of
IgG. With protein A scattered along the surface of the bacterium, this results in S. aureus
being covered with IgG antibodies that are oriented in the opposite way such that they
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cannot be recognized by Fcγ receptors on phagocytes. The importance of this defense
mechanism has been illustrated in both an arthritis and a subcutaneous murine infection
model in that the S. aureus strain lacking protein A showed attenuated virulence (56, 57).
Clumping factor A (ClfA) is another cell surface protein involved in masking S. aureus
from the host’s immune system by binding fibrinogen which is a protein found in blood
that is converted into fibrin in order for blood clots to form (58). While ClfA is the
primary protein involved in this process, other proteins, such as ClfB and the fibronectinbinding proteins also contribute to fibrinogen binding (59, 60). The end result is the
bacterium being coated with fibrinogen molecules, protecting S. aureus from
phagocytosis (61). Conversely, fibronectin has also been shown to form a bridge
between the fibronectin binding proteins and β1 integrins on nonprofessional phagocytes,
mediating the uptake of bacteria (62). S. aureus is able to survive intracellularly and this
action allows S. aureus to avoid complement and antibody-mediated host defense
mechanisms.
There are many other ways that S. aureus evades direct attacks by the immune system.
For example, when a neutrophil succeeds in phagocytosing S. aureus, a large proportion
of the bacteria are able to survive the neutrophil’s attack and emerge from the phagocyte
(63, 64). One of the ways it is able to do this is by producing staphyloxanthin, which acts
as an antioxidant to neutralize reactive oxygen species that are created by neutrophils (6,
7). S. aureus also produces a capsule that has been shown to protect itself from
phagocytosis by neutrophils in vitro (65). Although S. aureus is usually considered an
extracellular pathogen, phagocytes are not the only cells to which S. aureus is able gain
access. Previous studies have shown that intracellular survival of S. aureus within nasal
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epithelial cells, keratinocytes, and endothelial cells, among others, are responsible for
persistent infections (66–68). This is at least partly due to the formation of slowgrowing, small, hypo-pigmented cells, termed small colony variants, within these host
cells (69).
When S. aureus is not camouflaging itself within the interior of host cells, it must
withstand attack by various bactericidal compounds, such as cationic antimicrobial
peptides (AMPs). One way in which it does this is by modifying surface molecules such
as wall teichoic acids and membrane phospholipids in order to minimize the negative
charge of these molecules thereby lessening the attractive force for these AMPs (70, 71).
Additionally, S. aureus secretes staphylokinase and aureolysin, two proteins that
inactivate AMPs. Staphylokinase binds and neutralizes alpha-defensins which are AMPs
that are important in the innate immune system, and this activity has been shown to
increase bacterial protection in vivo (72). Aureolysin cleaves and incapacitates human
cathelicidin LL-37, another AMP (73). All of these factors, along with many others,
work together to protect S. aureus from attack by the immune system.

1.1.4

Antibiotic resistance

While MRSA was initially associated with hospital-acquired infections, this has changed
and now MRSA infections rapidly spread among otherwise healthy individuals.
Methicillin resistance first arose in S. aureus when it acquired the staphylococcal cassette
chromosome mec (SCCmec) mobile genetic element (74, 75). SCCmec is a large DNA
fragment that inserted near the origin of replication and was acquired relatively recently,
compared to other genes, as evidenced by atypical codon usage (76). The SCCmec
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element contains many genes including two recombinases, ccrA and ccrB, which are
conserved across all types of SCCmec elements identified and are required for its
movement (75). Importantly, the element contains the mecA gene as well as others that
are involved in the regulation of mecA. The mecA gene codes for penicillin-binding
protein 2a (PBP2a) which confers resistance to β-lactam antibiotics due to its binding of
β-lactams with a much lower affinity compared to other PBPs; therefore the antibiotics
cannot inhibit cell wall crosslinking to the degree that would be necessary for their
bactericidal action (77, 78).
Vancomycin is a glycopeptide antibiotic that acts by inhibiting cross-linking in the cell
wall by binding to the two terminal D-alanine residues in the peptide chains, and was first
made available in 1958 (79). It was considered the drug of last resort for MRSA
infections; however, S. aureus strains with varying levels of resistance to vancomycin
have been reported. Vancomycin intermediate S. aureus (VISA) was first identified in
1997 and vancomycin resistant S. aureus (VRSA) was reported in 2002 (80, 81). Strains
are currently defined as vancomycin susceptible at a broth MIC of ≤2 µg/mL,
intermediate at 4-8 µg/mL, and resistant at ≥16 µg/mL (82). VISA strains do not have a
resistance mechanism to vancomycin that was acquired by foreign transfer of DNA but
rather have an accumulation of mutations that leads them to better resist this antibiotic.
Some of these mutations in VISA strains that increase their resistance to vancomycin lead
to cell wall thickening, downregulation of protein A (spa), decreased acetate catabolism,
and increased capsule production (reviewed in reference 75).
VRSA strains are believed to have arisen from the transfer of the vanA gene from
vancomycin resistant enterococci (VRE) to S. aureus. The vanA gene has been found in
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VRSA isolates on a plasmid in an 11-kb transposon, Tn1546 (83). VanA is responsible
for the formation of D-Ala-D-Lac terminal peptides in place of the D-Ala-D-Ala amino
acids normally in peptide chains within the peptidoglycan. This changes the binding site
for vancomycin thus drastically decreasing its effectivity.
In addition to vancomycin and methicillin resistance, S. aureus can obtain resistance to a
number of other antibiotics, often mediated by plasmids, but also by transposon insertion
into the chromosome or mutations in certain pre-existing genes. For example,
chloramphenicol, tetracycline, and streptomycin resistance genes have been found on a
number of plasmids isolated from S. aureus (84). Resistance to the macrolides,
lincosamides, and streptogramins can be mediated by a chromosomal mutation in the 23S
rRNA gene, through numerous plasmids, or through a transposon insertion (85–88). Due
to the very mobile nature of these elements, the antibiotic resistance profiles of each
strain can be quite different, making antibiotic susceptibility testing in healthcare settings
very important.

1.1.5

USA300

Currently, there is one strain of CA-MRSA that is spreading across the world and is the
most common cause of MRSA infections in both the United States and Canada, among
other countries (89–92). This strain, USA300, was first identified in 2002 in Los
Angeles, California and was resistant to β-lactam antibiotics and commonly to
erythromycin; however, additional antibiotic resistance in this strain has been
documented (25, 93, 94). Causing even more concern is the emergence of USA300
isolates with increased vancomycin resistance, putting them in the VISA category (95,
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96). In terms of methicillin resistance, USA300 carries SCCmec type IV which is smaller
than the SCCmec types commonly carried by classic HA-MRSA strains (93). Due to its
small size, it has been postulated that SCCmec type IV is more mobile than other types
and has been transferred to MSSA strains over 20 times, presumably from coagulasenegative staphylococci (97).
USA300 is most commonly associated with skin and soft tissue infections but has also
been responsible for invasive infections including bloodstream infections, necrotizing
fasciitis, and pneumonia (25, 98–100). One reason why USA300 may be such a
successful pathogen is its increased production of a number of global virulence regulators
and virulence factors, including agr, saeRS, sarA, hla, and pvl (29). The PVL toxin is
encoded by two genes, lukS and lukF that are secreted and combine to form a pore in
polymorphonuclear neutrophils and was first identified in 1932 (101). There has been
considerable debate regarding the role of PVL in USA300 and whether it is responsible
for the observed increase in virulence and fitness associated with this strain and other
PVL+ strains (102–106).
Finally, another characteristic feature of the genome in USA300 is the presence of the
arginine catabolic mobile element (ACME) which is present in almost all USA300
isolates and is relatively infrequently found in other strains (107). The ACME encodes at
least 33 genes including those in the arc operon involved in arginine catabolism and the
opp operon, thought to be involved in oligopeptide uptake (108). It has been shown to
improve S. aureus survival in acidic conditions intended to mimic human sweat and also
to improve general fitness (107, 109). Importantly, it encodes the speG gene for
spermidine acetyltransferase (110). Spermidine is a polyamine involved in host wound
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healing that has a bactericidal effect on S. aureus; however, with the speG gene product,
USA300 is able to overcome sensitivity to spermidine and therefore speG may be an
important factor in the success of this strain.

1.2 Staphylococcal colonization
Various staphylococci are ubiquitously found on the skin of humans as part of the normal
flora, of which S. epidermidis is the most commonly found species. Other staphylococci
that are frequent or occasional colonizers include S. haemolyticus, S. cohnii, and S.
lugdunensis, among many others (111, 112). While many individuals colonized with
these bacteria will not experience infection caused by them, they are opportunistic
pathogens capable of causing a range of infections.
Together with these other staphylococci, S. aureus must compete for resources and
residency in its preferred habitat at the anterior nares. One study identified a negative
correlation between carriage of Streptococcus pneumoniae and S. aureus (113). In
another study, S. aureus carriage was found to be associated with a reduction in cocolonizing S. epidermidis and Propionibacterium acnes, indicating competition between
these microbes and suggesting opportunity to exploit this interaction for therapeutic gains
(114).
In 2010, a specific protein was identified that could be useful for inhibiting S. aureus
colonization. The researchers showed that a serine protease secreted by S. epidermidis,
Esp, is able to inhibit S. aureus nasal colonization (115). This was demonstrated in
human volunteers who were S. aureus carriers. When S. epidermidis producing Esp was
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added into the nasal cavity of these volunteers, S. aureus was eliminated; however, when
Esp non-producers were added, there was no impact on S. aureus carriage.
This is not the first time that eradication of colonization has been considered as a
preventative measure for S. aureus infections. Mupirocin has been utilized as a topical
antimicrobial for decolonisation of MRSA and acts by inhibiting bacterial protein
synthesis. Unfortunately, resistance arose in the form of a point mutation in the ileS gene
coding for the isoleucyl tRNA synthetase, which is the specific target of mupirocin, and
also through the acquisition of the mupA gene that codes for an alternate isoleucyl tRNA
synthetase to which mupirocin cannot bind (116). Regardless, the effectiveness of
mupirocin as a decolonizer or as a postoperative preventative measure has been
questioned and is moderate at best (117, 118).
There are also host factors that aid or prevent S. aureus colonization. One study found
that the presence of hemoglobin in human nasal secretions promoted S. aureus
colonization (119). Additionally, there have been several studies examining the impact
of single nucleotide polymorphisms (SNPs) in the host genome and how these relate to S.
aureus colonization. Associations have been made between persistent carriage of S.
aureus and SNPs in IL-4, CRP, CFH and NR3C1 (120, 121). Some disease states are
also correlated with an increased risk of S. aureus infection, such as cystic fibrosis and
diabetes (68, 122). There are many other host factors that are known to provide
protection against the invasion of pathogens, such as antimicrobial polypeptides (AMPs)
and antibacterial free fatty acids (FFAs).
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1.2.1

Human skin innate immunity - AMPs

The skin acts as the primary barrier to infection and thus represents our first line of
defense against invading microorganisms. In addition to simply being a mechanical
barrier, many compounds are secreted from various cell types to help protect us from
infection, such as antimicrobial peptides (AMPs). The biggest producers of AMPs in
human skin are keratinocytes, however once inflammation occurs and immune cells
arrive, leukocytes secrete a majority of the AMPs (123, 124). Two of the most studied
AMPs are human β-defensin 1 (hBD-1) and cathelicidin LL-37. HBD-1 is constitutively
expressed in keratinocytes but wasn’t thought to have significant antimicrobial activity
until it was identified that the reduction of disulphide bonds in this protein was required
for its full antibacterial effect (125). The exact mechanism of the antibacterial effect of
hBD-1 is not known, although it is generally attributed to its ability to disrupt
membranes, possibly due to their positive charge interacting with negatively charged
molecules on the surface of bacteria (126). Additionally, hBD-1 is involved in the
recruitment of various immune cells to the site of infection, thus it also exerts an indirect
antibacterial effect (127).
Conversely, cathelicidin LL-37 is normally expressed at very low levels in keratinocytes
but is upregulated in response to infection (128). It is also expressed constitutively in
epithelial cells and stored in neutrophil granules (129, 130). Cathelicidin LL-37 is
chemotactic for a variety of immune cells, thus recruiting these immune cells to the site
of infection (131). Additionally, cathelicidin LL-37 was shown to disrupt bacterial
membranes with increased effectiveness against gram-positive bacteria compared to
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gram-negatives (132). Cathelicidin LL-37 and hBD-1, along with other AMPs, are
important components of the innate immunity of our skin and they act alongside a variety
of free fatty acids, also with antimicrobial properties.

1.2.2

Antibacterial free fatty acids

The sebaceous glands are responsible for secreting sebum which has a high concentration
of triglycerides but also secretes AMPs (133). Sebaceous glands are found throughout
our body with the exception of our palms and soles. The majority of these are associated
with hair follicles and as such, are termed pilosebaceous glands while those that are not
are termed free sebaceous glands (134). Sebaceous glands secrete sebum as the mature,
lipid-filled cells die and lyse (135). The sebum is composed primarily of triglycerides,
wax esters, squalene, cholesterol, and free fatty acids (FFAs) and the FFAs are largely
produced by hydrolysis of the triglycerides (136, 137). Interestingly, the triglycerides are
known to be cleaved into FFAs by bacterial lipases and this further contributes to the
antimicrobial effect, as FFAs are the most active antibacterial component of sebum (138,
139).
One of the major FFA constituents of human sebum is sapienic acid (C16:1Δ6) and it has
been shown to have potent antimicrobial activity (138). Illustrating the importance of
sapienic acid in innate immunity, it was found that individuals with atopic dermatitis
often have a deficiency in sapienic acid and this was correlated to an increase in S. aureus
colonization (140). Other fatty acids, such as linoleic (C18:2Δ9,12), oleic (C18:1Δ9), and
palmitic (C16:0) acids were found to accumulate to high levels in staphylococcal
abscesses (2). However, in a separate study, oleic and palmitic acids were not found to
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be inhibitory toward S. aureus in vitro while linoleic acid was inhibitory, suggesting that
linoleic acid may be an important defense component in abscess formation (141). The
antibacterial effect of many FFAs has been well-documented and impacts a number of
factors, both in the host and the bacterium (142).
The characteristics of each fatty acid play a strong role on the strength of its antimicrobial
activity. For example, fatty acids of the same chain length are generally more potent
when unsaturated compared to saturated and potency is also increased with increasing
degrees of unsaturation (143, 144). Additionally, FFAs with double bonds in the trans
orientation have a larger effect compared to the cis orientation, likely due to the shape
this gives the molecule (144). In terms of the effect of FFAs on the skin, in addition to a
direct antibacterial action, they also create a hostile environment by reducing skin pH and
negatively impacting the production of bacterial virulence factors (140, 145, 146).
Although there has been significant evidence of an antimicrobial effect with these FFAs,
the mechanism of action has not been definitively elucidated. The majority of the
proposed mechanisms involve disruption of the bacterial membrane resulting in trauma to
the membrane and/or to the various processes that take place there (reviewed in reference
135). The FFAs likely insert into the bacterial cell membrane and disrupt the electron
transport chain and oxidative phosphorylation, impacting energy generation (146–148).
This could be achieved by displacing the protein components from the membrane
entirely, causing too much distance between them, or binding and inactivating them.
Additionally, FFAs may cause cell lysis, inhibit endogenous fatty acid synthesis, or
reduce nutrient uptake (142). While the exact direct effect of these FFAs has not been
conclusively shown, it is evident that these compounds inhibit bacterial growth likely
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through a disrupting effect to the membrane. This begs the question, if these FFAs are so
harmful to bacteria, how do they survive in FFA rich environments, such as the skin?

1.2.3

Resistance to fatty acids

The fatty acid composition of nasal secretions varies largely by individual but they are
found in micromolar concentrations in nasal secretions and accumulate in staphylococcal
abscesses (2, 149, 150). Nasal secretions contain FFAs at sub-inhibitory concentrations
for S. aureus and therefore S. aureus can survive under these conditions. Interestingly,
other bacterial species are able to utilize host-derived fatty acids as an energy source;
however this requires enzymes capable of beta-oxidation to break down the fatty acids
into two-carbon acetyl-coA molecules that can enter the TCA cycle. No enzyme with
this functionality has been identified in S. aureus and therefore, S. aureus is not thought
to be capable of using exogenous fatty acids for energy derivation (151, 152). As such,
inhibitors of fatty acid biosynthesis are potential antimicrobial candidates for S. aureus.
One natural resistance mechanism thought to exist in S. aureus is the fatty acid modifying
enzyme (FAME). While this enzyme has not been purified, nor has a gene been
identified, its activity has been documented in approximately 80% of S. aureus culture
supernatants (153, 154). The FAME functions to esterify the fatty acid to an alcohol
resulting in detoxification of the compound (154). Triglycerides containing unsaturated
free fatty acids are inhibitors of FAME activity (153) suggesting a potential
complementary role between FAME and bacterial lipases whereby lipases degrade
triglycerides and FAME detoxifies the resulting FFAs. Another study found that many
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coagulase-negative staphylococci also produce FAME and that there was a strong
correlation between the production of FAME and lipase (155).
Another way that S. aureus is thought to protect itself from FFAs is through the
modification of its cell wall or the proteins therein. The cell wall was shown to be
important as when bacterial cells lacked their cell wall, they were readily lysed by
various FFAs (156). In a similar vein, S. aureus mutants lacking wall teichoic acids
(WTAs) are more susceptible to FFA killing (157). WTAs are negatively charged and
may help to repel fatty acids by decreasing the hydrophobicity of the outer surface of the
bacterium. Another mechanism the cell employs to decrease hydrophobicity at its
surface is through the upregulation of IsdA, which is a surface-associated protein
involved in iron acquisition from hemoglobin (158). Researchers used human volunteers
to show that a ΔisdA mutant S. aureus strain was recovered in significantly lower
numbers compared to wild-type when allowed to colonize the forearms of these
volunteers (158). Recently, the identification and characterization of a novel FFA
resistance mechanism has been described in which farE, coding for an efflux pump, is
induced by a transcriptional regulator, FarR (159). Deletion of the farE gene resulted in
increased susceptibility to both linoleic and arachidonic acids, but not palmitoleic acid.

1.3 Research Hypothesis
We have previously shown that when grown in 50 µM linoleic acid, Staphylococcus
aureus experiences a 10-12 hour lag phase, followed by unimpeded growth (141). We
hypothesize that the growth observed in the presence of 50 µM linoleic acid is due to the
presence of, and selection for, mutants with a genetically-encoded resistance mechanism.
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1.3.1

Objectives

Objective 1: Obtain linoleic acid-resistant S. aureus mutants by performing growth in 50
µM linoleic acid and select single colonies for further analysis.
Objective 2: Identify genetic mutations associated with increased resistance by whole
genome sequencing.
Objective 3: Characterize the mechanism of linoleic acid resistance afforded to these
genetically altered S. aureus mutants.
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Chapter 2

2

Materials and Methods

2.1 Bacterial strains, storage, and growth conditions
Bacterial strains used in this study are listed in Table 1. All S. aureus strains were
cultured in TSB while E. coli strains were cultured in LB and stored at -80°C in 15%
glycerol. Strains were streaked on TSB (S. aureus) or LB (E. coli) agar and
supplemented with antibiotics when required: chloramphenicol at 10 µg/mL, kanamycin
at 40 µg/mL, or ampicillin at 100 µg/mL. USA300 LAC was a gift from Dr. B.
Kreiswirth and was cured of plasmid-mediated resistance by Jessica Sheldon. The
resulting strain, USA300, was used as the wild-type strain for all experiments.
For growth in fatty acids, a 5mM stock solution of fatty acid was made by adding an
equal volume of fatty acid and DMSO to TSB. To make a 5 ml solution of 5 mM linoleic
acid, 5 ml TSB was mixed with 7.78 µL DMSO and 7.78 µL linoleic acid (L1012,
Sigma-Aldrich, Oakville, Ontario). The required amount of this stock was then diluted
into the assay flasks or tubes containing TSB to reach the desired concentration. Aerobic
growth occurred at 37°C with shaking at 220 rpm, unless otherwise noted.
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Table 1. Bacterial strains used in this study
Strain

Description

S. aureus
USA300 LAC

Community-acquired MRSA isolate

USA300

USA300 LAC cured of antibiotic resistance
plasmid, wild-type strain
RN4220
rK- mK+ ; lab strain capable of accepting foreign
DNA
CS1
USA300 CvfAL269F
CS2
USA300 CvfAQ333K
CS3
USA300 CvfAV287D
CS4
USA300 CvfAS330N
CS5
USA300 CvfAP280L
USA300 + pALC USA300 containing empty pALC2073 vector
USA300 + pWT USA300 containing pΔtetR expressing wild-type
CvfA
USA300 + pCS1 USA300 containing pΔtetR expressing CvfAL269F
USA300 + pCS2 USA300 containing pΔtetR expressing CvfAQ333K
USA300 + pCS3 USA300 containing pΔtetR expressing CvfAV287D
USA300 + pCS4 USA300 containing pΔtetR expressing CvfAS330N
USA300 + pCS5 USA300 containing pΔtetR expressing CvfAP280L
E.coli
DH5α

BL21 (DE3)

BL21 + pET
BL21 + p-TM

BL21 + pML3
BL21 + pML4

Source or reference

(99)
Dr. Kreiswirth
(141)
(160)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

F- Φ80lacZΔM15 Δ(lacZYA-argF)
U169 recA1 endA1 hsdR17(rk-,
mk+) phoAsupE44 thi-1 gyrA96 relA1 λfhuA2 [lon] ompT gal (λ DE3) [dcm] ΔhsdS λ DE3
= λ sBamHIo ΔEcoRI-B int::(lacI::PlacUV5::T7
gene 1) i21Δnin5
BL21 containing empty pET28a(+) vector; Kmr

Life Technologies

BL21 containing pET28a(+) expressing wild-type
CvfA lacking its transmembrane domain and with
an N-terminal histidine tag
BL21 containing pET28a(+) expressing full length
wild-type CvfA with a C-terminal histidine tag
BL21 containing pET28a(+) expressing full length
CvfAL269F with a C-terminal histidine tag

This study

(161)

This study

This study
This study
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2.2 DNA methodology
2.2.1

Polymerase chain reaction (PCR)

For cloning, PCR was performed using phusion polymerase (New England Biolabs)
following the manufacturer’s protocol in 50 µL reactions. For checking transformants,
PCR was performed using Taq polymerase (New England Biolabs) and 20 µL reactions.
PCRs were performed in the DNA engine Gradient Cycler (Bio-rad) or the MJ Mini
Personal Thermal Cycler (Bio-rad). Annealing temperatures were determined using the
New England Biolabs online Tm calculator based on primers and polymerase. Primers
used in this study are listed in Table 2. Following amplification, PCR products were
visualized on a 0.8% (w/v) agarose gel stained with SYBR® safe (Invitrogen) and
cleaned using a QIAquick PCR purification kit (Qiagen).
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Table 2. Primers used in this study
Name
CvfA_clonF
CvfA_clonR
noTM_F
noTM_R
FullCvfA_F
FullCvfA_R
AddHis_F
AddHis_R
a

Sequencea
CCCGGTACCCCTAGAAAAGGAGGTGTTTGTGTG
CCCGAGCTCACCGATAAAGTGCTGTCTAACTAGA
CCCCATATGTTGCTTCAAAAGCAATCACAAGC
CCCGAATTCACCGATAAAGTGCTGTCTAACTAGA
TTTCCATGGTGAATTTATTAAGCCTCCTA
TTTGGATCCTTAGTGGTGGTGGTGGTGGTGTTTCGCATATTCTAC
TGCTCTAG
TTTAACCGCGGCAGAACCACGCGGAACCAGTTTCGCATATTCTA
CTGCTCTA
TTTGCCGCGGTTCATCATCATCATCATCATCACCACCACCACCA
CCACTAAGGATCCAAA

Restriction digestion sites are underlined; KpnI (GGTACC); SacI (GAGCTC); NdeI (CATATG); EcoRI
(GAATTC); NcoI (CCATGG); BamHI (GGATCC); SacII (CCGCGG)
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2.2.2

Restriction enzyme digestion and DNA ligation

Restriction enzymes were purchased from New England Biolabs and used according to
the manufacturer’s directions. Double digests were performed in 50 µL volumes with
approximately 1 µg of DNA with the appropriate reaction buffer. The reaction mixture
was incubated for 2-4 hours at 37°C and cleaned using a QIAquick PCR purification kit,
following manufacturer’s protocols (Qiagen). Digested plasmids were isolated from
agarose gels using the QIAquick Gel Extraction Kit (Qiagen). DNA fragments and
plasmids were ligated using the T4 DNA ligase Rapid Ligation Kit (Roche) in a 20 µL
reaction volume. A 10:1 molar ratio of insert to vector was used for plasmid
construction.

2.2.3

DNA isolation from E. coli and S. aureus

Plasmids were isolated using the E.Z.N.A. Plasmid Miniprep Kit (Omega Biotek)
following the manufacturer’s protocol and are listed in Table 3. For plasmid preparation
from S. aureus, cell pellets were resuspended in 250 µL Solution I/RNase containing 10
µg lysostaphin (Sigma). This mixture was incubated for approximately 1 hour at 37°C
before the addition of Solution II.
Genomic DNA from S. aureus was isolated for sequencing using the Invitrogen genomic
DNA isolation kit following the manufacturer’s protocol. For checking transformed
colonies, DNA was isolated from S. aureus by resuspending a colony in 100 µL lysis
buffer (25 mM tris-HCl, 50 mM glucose, 150 mM NaCl, 10 mM EDTA, pH 8.0)
containing 4 µg lysostaphin and incubating for approximately 1 hour at 37°C to obtain
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complete cell lysis. Two microliters of 10% (w/v) SDS was added before heating to
95°C for 10 minutes and cooling to room temperature. An equal volume (102 µL) of
phenol:chloroform was added and the solution was mixed by inversion. Following a 30
minute incubation at room temperature, the sample was centrifuged for 10 minutes at
13000 × g and the aqueous phase was transferred to a fresh tube and diluted 10-fold.
This sample contained genomic DNA and was used as the template for subsequent
reactions.

28

Table 3. Plasmids used in this study
Plasmid

Descriptiona

pALC2073

E. coli/S. aureus shuttle vector with
anhydrotetracycline-inducible expression; Ampr
in E. coli, Cmr in S. aureus
pALC2073 with the TetR repressor gene deleted
pΔTetR expressing wild-type CvfA
pΔTetR expressing SNP-containing CvfA from
strain CS1 (CvfAL269F)
pΔTetR expressing SNP-containing CvfA from
strain CS2 (CvfAQ333K)
pΔTetR expressing SNP-containing CvfA from
strain CS3 (CvfAV287D)
pΔTetR expressing SNP-containing CvfA from
strain CS4 (CvfAS330N)
pΔTetR expressing SNP-containing CvfA from
strain CS5 (CvfAP280L)
Expression vector for E. coli carrying an Nterminal His tag, thrombin recognition sequence,
and T7 terminator; Kmr
pET28a(+) expressing wild-type CvfA lacking its
transmembrane domain and with an N-terminal
histidine tag
pET28a(+) expressing full length wild-type CvfA
with a C-terminal histidine tag
BL21 containing pET28a(+) expressing full
length CvfAL269F with a C-terminal histidine tag

pΔTetR
pWT
pCS1
pCS2
pCS3
pCS4
pCS5
pET28a (+)

p-TM

pML3
pML4
a

Source or reference
(162)

Jessica Sheldon
This study
This study
This study
This study
This study
This study
Novagen

This study

This study
This study

Ampr, Cmr, and Kmr designate resistance to ampicillin, chloramphenicol, and kanamycin, respectively
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2.2.4

Plasmid construction

The construction of S. aureus complementation vectors was completed using the
CvfA_clonF and CvfA_clonR primers to amplify cvfA from the appropriate S. aureus
strain. Following digestion as described, the amplified fragments were ligated into
pΔtetR. The pΔTetR plasmid was derived from pALC2073 and constructed by Jessica
Sheldon via allelic replacement of the tetR gene through the use of the pKOR1 vector.
For the expression of CvfA lacking its transmembrane domain in E. coli, we used the
noTM_F and noTM_R primers, amplified cvfA, digested, and ligated into pET28a(+).
We employed the FullCvfA_F and FullCvfA_R primers for cloning full length CvfA into
pET28a(+) and this resulted in expression of CvfA with the addition of six histidines at
its C-terminus. We later added a thrombin recognition sequence and an additional six
histidine residues by insertional mutagenesis. Using the AddHis_F and AddHis_R
primers, we amplified the existing plasmid. The resulting mixture was cleaned using a
QIAquick PCR purification kit (Qiagen) and then digested with DpnI to degrade the
methylated template DNA.

2.3 Transformation methodology
2.3.1

Preparation of transformation competent E. coli and S.
aureus

E. coli DH5α and BL21 were made chemically competent by growing a 100 ml culture in
LB broth to an OD600 of 0.5, followed by a 20 minute incubation on ice. Cells were
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pelleted and resuspended in 25 ml cold 0.1 M CaCl2, 15% (v/v) glycerol. Following
another 30 minute incubation on ice, cells were pelleted again and resuspended in 1 ml of
cold 0.1 M CaCl2, 15% (v/v) glycerol. Cells were stored in 100 µL aliquots at -80°C.
S. aureus RN4220 or USA300 was made electrocompetent by growing a culture in 100
ml TSB at 37 °C until the OD600 reached 0.3. The flask was put on ice for 10 minutes
prior to pelleting cells and resuspending in 10 ml of cold 0.5 M sucrose. Cells were
pelleted and resuspended in 1 ml cold 0.5 M sucrose twice and 60 µL aliquots were
stored at -80°C.

2.3.2

Transformation of competent E. coli and S. aureus

Plasmid DNA (100-1000 ng) was added to competent E. coli cells that were thawed on
ice, and this mixture was incubated on ice for 30 minutes. The cells were moved to 42°C
for two minutes then back to ice for two minutes, after which 900 µL of LB broth was
added and the mixture was incubated at 37 °C for 1-2 hours. Aliquots of 100 µL were
plated on selective agar and incubated at 37 °C overnight to allow colony growth. All
plasmid sequences were confirmed by Sanger sequencing which was completed by the
London Regional Genomics Centre (LRGC) at the Robarts Research Institute.
Electrocompetent S. aureus cells were thawed on ice and 50-1000 ng of plasmid was
added, followed by a 30 minute incubation on ice. Cells were transferred to a cold
electroporation cuvette (2mm, Bio-Rad) and electroporated using a Bio-Rad Gene Pulser
II at 200 ohms, 25 µF, and 2.5 kV. 940 µL of TSB was then added to the cuvette and
cells were transferred to a microfuge tube. Following 2-4 hours at 37 °C, cells were
plated on selective TSA and incubated overnight at 37 °C.
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2.4 Selection of linoleic acid resistant mutants
We have previously shown that S. aureus undergoes a 10-12 hour lag phase when grown
in TSB with 50 µM linoleic acid (141). To select for mutants with a genetically encoded
resistance mechanism, we took the cells that had grown up after one round of growth in
TSB with 50 µM linoleic acid, sub-cultured twice in TSB alone, then back into TSB
containing 50 µM linoleic acid. All cultures were grown at 37°C and 220 rpm in 125 ml
flasks containing 25 ml TSB with or without 50 µM linoleic acid. This was performed
with seven separate cultures, and dilutions of each of the final cultures were plated to
isolate single colonies. One colony from each of the biological replicates was selected
and genomic DNA was isolated using the Invitrogen genomic DNA isolation kit
following the manufacturer’s protocol.

2.5 Genome sequencing
Genomic DNA from the fatty acid resistant clones and from a wild-type USA300 strain
were sent for processing and sequencing at the LRGC to identify potential resistanceconferring mutations. Samples were quantified, fragmented, and sample-specific
adapters were ligated to the fragments. The appropriate size fragments were selected for
and following several quality checks, the genomes were sequenced using the Ion Torrent
Personal Genome Machine (Life Technologies, Carlsbad, CA). Sequences were analyzed
using CLC Bio Genomics Workbench (CLC Inc., Aarhus, Denmark) and mapped to the
published genome of S. aureus subsp. aureus USA300_FPR3757. SNPs were identified
using the neighbourhood quality standard algorithm (163) and SNPs that were present in
both the wild-type strain as well as the fatty acid resistant strains were discounted.
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2.6 Minimum inhibitory concentration and viability assays
To characterize the phenotypes and resistance profiles of the fatty acid resistant strains,
MIC and viability assays were performed. A stock solution containing 5 mM fatty acid
in TSB was made as described in section 2.1. For the MICs, 240 µL of this stock was
added to a glass tube containing 1.76 ml TSB and vortexed, resulting in a final
concentration of 600 µM fatty acid. Two-fold serial dilutions were then performed down
to 37.5 µM. For viability assays, 125 ml flasks with 25 ml TSB were made 100 µM with
respect to linoleic acid.
Biological triplicates of appropriate strains were grown overnight in TSB with
chloramphenicol. All strains were sub-cultured into fresh TSB at an OD600 of 0.01. For
MICs, when cultures reached an OD600 of 1, they were inoculated to an OD600 of 0.01
into glass tubes containing 1 ml TSB with the indicated concentration of fatty acid.
Culture growth was assessed at the 24 hour time point to determine the MIC. For
viability assays, cultures were also harvested at an OD600 of 1 but were inoculated into
flasks at an OD600 of 0.05. An aliquot of each culture was taken at the indicated time
points and plated to determine CFUs.

2.7 Uptake of 14C-linoleic acid
For further characterization of the fatty acid resistant strains, radioactive uptake assays
were performed similar to that described in a previous report (159). Strains were grown
in triplicate in 25 ml TSB from an OD600 of 0.01 to approximately 0.5 at which point a 1
ml aliquot was taken and supplemented with 0.2 µCi/mL of 14C-linoleic acid. A 200 µL
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aliquot from each sample was removed at 3, 5, 10, and 15 minute time points and the
samples were placed on 0.45 µm pore-size filter discs connected to a vacuum manifold.
The cells were washed twice with 4 ml of buffer (0.1 M Na-phosphate pH 7, 1% Triton
X-100) and placed in scintillation vials. The discs were allowed to dry and then 4 ml of
Cytoscint scintillation cocktail (Fisher Scientific) was added.
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C-linoleic acid within

cells was then measured using a Beckman LS 6500 scintillation system. Data were
normalized by total protein content based on OD600.

2.8 RNA sequencing
Given that CvfA is an RNase, an RNA sequencing assay was performed to identify
transcripts that are impacted by the L269F mutation. Six biological replicates of wildtype USA300 and CS1 were diluted to an OD600 of 0.01 in 25 ml TSB with 15 µM
linoleic acid and grown to an OD600 of one. Three OD units were pelleted and washed
with 750 µL of TE buffer (10 mM Tris-HCl, 1 mM EDTA). After centrifugation, the
pellet was resuspended in 100 µL of 500 µg/mL lysostaphin in TE buffer and samples
were frozen overnight at -80°C. Upon thawing, the samples were incubated for 1 hour at
37°C. The samples were then processed to obtain RNA using the AurumTM Total RNA
Mini Kit (Bio-rad). The kit was used according to the manufacturer’s protocol with the
addition of a second DNase I treatment (Roche), and the samples were stored at -80°C.
The RNA quality and quantity was checked on an agarose gel and using a Nanodrop
(Thermo Scientific) prior to being sent to the LRGC for analysis on the Agilent 2100
BioAnalyzer (Agilent Technologies, Palo Alto, CA). The four highest quality samples
for both USA300 and CS1 were chosen to continue. For removal of rRNA, we employed
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the MICROBExpressTM Kit (Life Technologies) and followed the manufacturer’s
protocol. The mRNA samples were sent for quality analysis on the BioAnalyzer by the
LRGC and the top three samples of each were selected to be sequenced. Samples were
processed by the LRGC according to the TruSeq Stranded mRNA Library Prep Kit and
protocol (Illumina) and sequenced using the MiSeq (Illumina). Samples were
fragmented, converted to cDNA, and adapters were ligated to allow samples to be pooled
and sequenced on the same flow cell.
Data was obtained in the form of fastq files and analyzed using CLC Bio Genomics
Workbench (CLC Inc., Aarhus, Denmark) following the user manual for RNAseq
analysis. Briefly, the fastq files were mapped to the USA300_FPR3757 genome and
expression values were normalized by RPKM (reads per kilobase of transcript per million
mapped reads). The normalized values of the three wild-type samples were compared to
those of the three CS1 samples and a t-test was used to determine p-values.

2.9 Secreted protein profiles
Upon evaluation of the RNA sequencing data, several virulence factors were identified as
being down-regulated and to follow up on this observation, we performed a TCA
precipitation of culture supernatants to look for differences in secreted protein profiles.
Strains were grown overnight in TSB and diluted to OD600 = 0.01 in 25 ml TSB with 15
µM linoleic acid. Cultures were grown for 18 hours at which point the OD600 was
determined and the cultures were centrifuged at 3,000 × g and 4°C for 30 minutes. Three
OD units worth of supernatant were removed and an equal volume of cold 20%
trichloroacetic acid was added and mixed, and samples were stored at 4°C overnight to
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precipitate proteins. Samples were spun at 13,000 rpm and 4°C for five minutes, the
supernatant was discarded, and the pellet was washed three times with cold 70% ethanol.
Following the final wash, the supernatant was discarded and the pellets were left to air
dry at 37°C for one hour. The samples were resuspended in 20 µL of Laemmli sample
buffer and run on an 11% SDS polyacrylamide gel at 100 volts for 90 minutes, after
which they were stained with Coomassie brilliant Blue R-250.

2.10 Hemolysin production
To evaluate hemolysis differences, strains were streaked on tryptic soy agar with or
without chloamphenicol, as required, and incubated overnight at 37°C. Single colonies
from these plates were picked and streaked on TrypticaseTM Soy Agar w/5% sheep blood
(Becton, Dickinson and Company, Sparks, MD) and incubated overnight at 37°C
followed by 4°C for 4 hours.

2.11 Subcutaneous infection model
A subcutaneous abscess model was chosen to evaluate the impact of the CvfAL269F
mutation in vivo. Cultures of USA300 or CS1 were grown to an OD600 = 1 in TSB and
sub-cultured into 25 ml TSB at an OD600 of 0.02. Cultures were grown until the OD600
was approximately 2.5 and then spun at 3,000 × g for 10 minutes and washed twice with
25 ml sterile phosphate-buffered saline (PBS). Cultures were diluted to an OD600 of 0.40
in PBS and dilutions were plated to determine CFUs.
Six-week-old BALB/c mice were purchased from Charles River Laboratories
(Wilmington, MA) and housed in microisolator cages. Twenty mice were anesthetized
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with isoflurane, their right flanks shaved and remaining hair removed with NairTM cream.
They were injected with 50 µL of the bacterial suspension containing 4-7 x 106 CFUs of
USA300 or CS1 under the skin of the flank. Each mouse was injected with one strain of
bacteria in one flank only. Images of the resulting abscesses were taken daily with a size
marker in frame for measurement. The images of the abscesses were measured using
FIJI (164). All animal protocols were approved by the University of Western Ontario's
Animal Use Subcommittee.

2.12 Protein expression and purification
To evaluate the impact of the L268F mutation on protein function, the protein was
expressed with or without its transmembrane domain in E. coli to be purified and tested.
E. coli BL21 cells containing the vector control or plasmids expressing CvfA were grown
overnight in LB with kanamycin. They were diluted to an OD600 of 0.01 in 500 ml LB +
kanamycin and grown to an OD600 of 0.6-0.8. An aliquot corresponding to 1 OD unit
was taken and cells from that aliquot were pelleted and resuspended in 100 µL 0.9%
saline to serve as the uninduced control. Additionally, the culture was made 0.4 mM with
respect to IPTG to induce expression off of the vector overnight at room temperature with
shaking. The next day, the OD600 was measured and another aliquot corresponding to 1
OD unit was taken to serve as the induced control. Efficient induction was evaluated by
visualization of the controls on a polyacrylamide gel stained with Coomassie brilliant
Blue R-250.
The culture post-induction was pelleted at 5,000 rpm and 4°C for 20 minutes and then
resuspended in 15 ml of phosphate buffer (100 mM Na-phosphate pH 7.4, 250 mM NaCl,
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10% glycerol). Samples were passed through a cell disrupter (Constant Systems Inc.) at
30 lb/in2 and spun at 3,000 × g and 4 °C for 20 minutes to pellet any insoluble material.

2.12.1

Inclusion body Purification

The construct producing CvfA lacking its transmembrane domain pelleted as inclusion
bodies. This pellet was washed four times with 25 ml of PBS + 1% Triton X-100 and
spins were performed at 3,000 × g and 4°C for 30 minutes. Another four washes were
performed using 25 ml PBS and increasing concentrations of NaCl: 0 mM, 150 mM, 300
mM, and 500 mM NaCl. The resulting pellet was denatured in 25 ml of 8 M urea in PBS
and left overnight at 4°C with stirring.
An ultracentrifugation was performed at 25,000 rpm and 4°C for 45 minutes to pellet
anything that did not solubilise after the overnight treatment in urea. The solution was
diluted ten-fold in PBS to decrease the concentration of urea to 0.8 M and left overnight
at 4°C with stirring. The next day, the protein sample was dialyzed against 2 L of PBS
and the buffer was exchanged 4 times over 48 hours to rid the protein-containing solution
of all remaining urea. The dialyzed product was collected by centrifugation at 3,000 × g
and 4°C for 30 minutes resulting in a soluble fraction and a small amount of precipitate.
The supernatant was concentrated using Amicon Ultra 30k centrifugal filters (EMD
millipore), visualized on a polyacrylamide gel, and the concentration was determined via
Bradford assay (Bio-Rad Protein Assay Dye Reagent Concentrate).
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2.12.2

Membrane purification

The constructs producing full length CvfA were expected to localize to the membrane.
Following cell lysis and the low speed spin to pellet any insoluble material, membranebound CvfA from BL21 + pML3 and BL21 + pML4 as well as the vector control, were
found in the supernatant. The supernatants were carried through to an ultracentrifugation
at 50,000 × g and 4°C for 45 minutes after which CvfA was found in the pelleted
membrane fraction. The membranes were resuspended in 1 mL of phosphate buffer (100
mM Na-phosphate pH 7.4, 250 mM NaCl, 10% glycerol) containing 2% n-dodecyl β-Dmaltoside (DDM). The samples were sonicated four times for 30s each and the insoluble
fraction was pelleted with an ultracentrifugation at 100,000 × g and 4°C for 30 minutes.
The supernatant was saved and the pellet was resuspended in 1 ml of phosphate buffer
containing 2% octyl-β-D-glucopyranoside (OG). The samples were sonicated and
centrifuged again as described and the pellet was resuspended in hepes buffer (50 mM
hepes-KOH pH 8, 20% glycerol) containing 2% tween-20. Following another sonication
and centrifugation, the result was three solubilised membrane fractions in three different
detergents. The samples were visualized by PAGE and protein concentrations
determined via Bradford assay.

2.13 Phosphodiesterase activity assay
To test for activity of both wild-type CvfA and CvfAL269F, a phosphodiesterase assay was
employed and adapted from a previous report (165). A 2X-stock buffer was made (100
mM hepes-KOH pH 9, 1.2 M KCl, 2 mM MnCl2) and 100 µL was aliquoted into each
well of a 96 well plate. Protein solutions were diluted to 0.4 µg/µL and 50 µL was added
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to each well, resulting in 20 µg of protein in each well. 50 µL of protein buffer (50 mM
hepes-KOH pH 8, 20% glycerol, 2% Tween-20) was added into the blank wells instead
of the protein solution and a separate blank well was used for each concentration of bis-4NPP. Additionally, protein samples were treated with DEPC to a final concentration of
1% in 50 µL to demonstrate that phosphodiesterase activity could be abolished. A 60
mM bis-4-NPP stock solution was made and the appropriate amount was added to each
well to make 0, 1, 3, 5, 10, and 15 mM solutions and water was added to each well to
achieve a final volume of 200 µL. The plate was incubated at 37°C and the A405 nm was
read at 3 hours. The enzyme activity was calculated using an extinction coefficient for 4nitrophenyl phosphate of 17,800 M-1 cm-1.

2.14 Pulldown assay
Finally, to examine whether the L269F mutation in CvfA impacts protein interactions, a
pulldown assay was performed with purified CvfA and whole cell lysate. USA300 whole
cell lysate was prepared by growing a 500 ml culture to an OD600 of 1-1.5, pelleting the
cells, and resuspending in 15 ml of phosphate buffer (50 mM Na-phosphate, pH 8) with
40 mM imidazole and one cOmpleteTM mini EDTA-free protease inhibitor cocktail tablet
(Roche). Cells were lysed with multiple passages through a cell disrupter (Constant
Systems Inc.) at 30 lb/in2 and any insoluble material and unbroken cells were pelleted by
centrifugation at 3,000 × g and 4°C for 20 minutes. The supernatant was collected as the
whole cell lysate and the protein concentration determined via Bradford assay.
DDM-solubilised protein samples were mixed with 1 mg of whole cell lysate and the
final concentration of DDM was adjusted to 1% and imidazole was kept at 40 mM. After
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a 20 minute incubation with rotation at room temperature, this mixture was added to 25
µL (1 mg) of Dynabeads TALON (Invitrogen). Following a second incubation with
rotation for 20 minutes at room temperature, the tubes were placed on a magnet to
separate the beads. The supernatant was collected as the unbound fraction and the beads
were washed three times with 200 µL of buffer (50 mM Na-phosphate pH 8, 50 mM
imidazole + 1% DDM). The suspension was transferred to a clean tube during the second
wash. Proteins were eluted from the beads with the addition of 20 µL laemmli buffer
containing 1 M imidazole and a 15 minute incubation with rotation. As negative and
positive controls, whole cell lysate and a DDM-solubilised protein sample were each
incubated with the beads separately. Washes and the elution were completed as
described above and all samples were visualized by SDS-PAGE.
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Chapter 3

3

Results

Our skin is rich with antimicrobial compounds and yet there are many microbes making
up the normal flora found there, of which Staphylococcus aureus is a common
component. In the following work, we selected for mutants of S. aureus with increased
resistance to antibacterial free fatty acids. We obtained and characterized mutants with
genetically-encoded mechanisms of resistance and began the elucidation of the molecular
mechanism underpinning the observed increased resistance.

3.1 Adaptation of S. aureus to growth in linoleic acid
Our lab has previously demonstrated that S. aureus growth is not inhibited in 25 µM
linoleic acid, while 50 µM produces a 10-12 hour lag phase, and 100 µM is inhibitory
(141). The growth after a significant lag phase in 50 µM linoleic acid suggested the
presence of a single colony that was capable of growth in this media and required 10
hours before a detectable level of growth had occurred. It was hypothesized that the
surviving bacteria possessed either a genetic mutation or an epigenetic change that
allowed growth. To evaluate this hypothesis, S. aureus was grown in 50 µM linoleic acid
and, following the lag phase, the cells that had grown to stationary phase were cultured
twice in rich media alone, and then subsequently back into media containing 50 µM
linoleic acid. During the second round of growth in linoleic acid-containing media, there
was no longer a lag phase observed and these cells were able to grow immediately
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(Figure 1). This suggested the presence of a heritable genetic change rather than an
epigenetic one as the phenotype was maintained through successive growth cycles
lacking linoleic acid.
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Figure 1. Staphylococcus aureus USA300 growth in successive cycles of linoleic acid.
S. aureus was grown in rich media containing 50 μM linoleic acid (open squares) or in
rich media alone (open circles). Cells that had grown up in linoleic acid were cultured
twice in rich media alone and then back into media containing 50 μM linoleic acid (open
triangles). The mean of three replicates ± standard error of the mean is plotted. Data
used with permission from Ben Arsic.
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3.2 Identification of SNPs in cvfA
In an attempt to confirm that a genetic change was associated with this linoleic acid
resistant phenotype and to identify this mutation, the genomes of seven linoleic acidresistant clones were sequenced using an Ion Torrent Personal Genome Machine (Life
Technologies, Carlsbad, CA). Two of these clones, CS1 and CS2, had distinct SNPs in
the same gene, cvfA. Intrigued by this finding, 10 additional independent cultures of
USA300 were grown, as above, to select for additional resistant clones. Anticipating that
additional SNPs may be identified in cvfA, the cvfA gene was amplified from each and
sent for traditional Sanger sequencing. This resulted in the identification of three more
independently isolated clones with SNPs in cvfA (CS3, CS4, and CS5). In total, five
linoleic acid resistant S. aureus mutants have been identified with SNPs in this gene
(Table 4).
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Table 4. Single nucleotide polymorphisms in S. aureus USA300_1179 (cvfA)

a

Strain

Gene

CS1

USA300_1179

CS2

USA300_1179

CS3

USA300_1179

CS4

USA300_1179

CS5

USA300_1179

SNPa
1298394
CT
1298586
CA
1298449
TA
1298578
GA
1298428
CT

Codon Change

Amino Acid
Substitution

CTTTTT

Leu269Phe

CAAAAA

Gln333Lys

GTCGAC

Val287Asp

AGTAAT

Ser330Asn

CCACTA

Pro280Leu

SNP, single nucleotide polymorphism. Number refers to the nucleotide position in the genome
of USA300_FPR3757.
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The cvfA gene is also referred to as RNase Y as it is the homolog of RNase Y in Bacillus
subtilis and the functional equivalent of RNase E in Escherichia coli (166). It was first
identified in S. aureus in 2005 when researchers obtained a knockout mutant of this gene
and observed attenuated virulence in a silkworm infection model, naming the gene
conserved virulence factor A (cvfA) (167). CvfA has been shown to act as part of the
degradosome complex in S. aureus, which is a multi-protein complex responsible for
bulk mRNA degradation. In particular, CvfA is known to dimerize, and interact directly
with CshA and Enolase, and indirectly with RNases J1 and J2, PNPase, Pfk, and RnpA
(168). CvfA itself is a membrane-bound RNase with mapped domains for dimerization,
RNA-binding, and catalytic activity, however binding sites for protein partners are
currently unknown (Figure 2).
The five mutated amino acid positions identified in linoleic acid resistant clones are
outlined in Figure 2. All of these mutations are located in the same region of CvfA,
largely in a domain of unknown function, with outliers on the edges of the RNA-binding
and catalytic domains. Given that the region within CvfA that is responsible for
facilitating protein-protein interactions is unknown, we hypothesized that SNPs in the
cvfA gene engender S. aureus with increased resistance to unsaturated free fatty acids
through altered interactions with degradosome partners (see section 3.7 for the
biochemical characterization of the CvfA protein).

47

Figure 2. CvfA domain architecture and location of SNPs. The CvfA protein is a
membrane protein with one transmembrane domain (TM), a coiled-coil domain to allow
dimerization, a KH domain for RNA binding and an HDc domain responsible for its
catalytic activity as a phosphodiesterase. The 5 mutated amino acid positions identified
in linoleic acid resistant clones are indicated and located in a region with unknown
function.
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3.3 Fatty acid resistant phenotype is specific to linoleic and
arachidonic acids
Although mutations in cvfA were confirmed in each of the 5 linoleic acid resistant clones,
these SNPs needed to be confirmed as the cause of increased resistance. Minimum
inhibitory concentration (MIC) assays were performed to characterize these clones and
identify their FFA resistance profiles. We observed a greater than 4-fold increase in the
MIC of linoleic and arachidonic acids for all five cvfA mutants (Figure 3). For linoleic
acid, the MIC increased from 150 µM for wild-type USA300 to greater than 600 µM for
the SNP-containing strains, with 600 µM being the highest concentration tested.
Similarly for arachidonic acid, there was a 4-fold increase in MIC from 75 µM to 600
µM. The cvfA SNP-containing strains did not have an increased MIC to other
unsaturated FFAs tested.
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Figure 3. Minimum inhibitory concentration of various fatty acids on wild-type S. aureus
USA300 and cvfA SNP mutants (CS1-5). Exponential phase cultures were inoculated at
an OD600 of 0.01 into glass tubes containing 1 ml TSB with the indicated amount of fatty
acid and growth was assessed after 24 hours. MIC assays were performed using linoleic
(A), arachidonic (B), sapienic (C), palmitoleic (D), and linolenic (E) acids and repeated
in triplicate.
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To confirm that these SNPs were alone responsible for the increased linoleic acid
resistance, the wild-type or SNP-containing cvfA gene was cloned into a plasmid that was
introduced into wild-type USA300. This cross-complementation approach was taken in
lieu of traditional complementation of a gene knockout strain because our attempts to
knock out cvfA from the chromosome were unsuccessful.
Strain USA300 expressing the cvfA genes from CS1, CS3, and CS5 fully recapitulated
the resistance phenotype for both linoleic and arachidonic acids (Figure 4). The strain
cross-complemented with cvfA from CS4 had a full increase in MIC of arachidonic acid
and a slight increase for linoleic acid, and the strain cross-complemented with cvfA from
CS2 had a moderate increase in MIC for both fatty acids. These MICs illustrated that the
SNPs in cvfA are indeed responsible for increased resistance to linoleic and arachidonic
acids. The SNPs in cvfA in strains CS2 and CS4 may require elimination of wild-type
cvfA from the genome to appreciate their full effect.
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Figure 4. The MIC of linoleic and arachidonic acids on cross-complemented strains.
MIC assays were performed as described previously using linoleic and arachidonic
acids with the addition of chloramphenicol in the overnight pre-cultures. USA300 +
pALC is the empty vector control while the other strains are cross-complemented
with the indicated cvfA gene (wild-type or SNP-containing). Experiments were
performed using biological triplicates.
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To gain an appreciation of the immediate impact of FFAs on wild-type or SNPcontaining bacteria, we performed a killing assay using 100 µM linoleic acid. All strains
were initially impacted by the presence of linoleic acid however CS1 was significantly
better able to withstand the toxicity of linoleic acid compared to wild-type USA300
(Figure 5a). Viability of USA300 cross-complemented with wild-type cvfA was below
detectable limits throughout the experiment and USA300 + pCS1 was impacted by the
linoleic acid to a greater degree than CS1; however, we eventually saw recovery of this
strain by ten hours (Figure 5b). The increased sensitivity observed in USA300 + pCS1
compared to CS1 may be explained by the presence of wild-type cvfA in addition to SNPcontaining cvfA. These data, along with the MICs, demonstrate that SNPs in cvfA protect
S. aureus against toxic and inhibitory concentrations of linoleic acid.
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Figure 5. The viability of S. aureus strains grown in 100 µM linoleic acid over 5 hours.
Exponential phase cultures of wild-type and CS1 (A) or strains cross-complemented with
wild-type or SNP-containing cvfA (B) were inoculated to an OD600 of 0.05 into 25 ml
TSB containing 100 µM linoleic acid and an aliquot was removed every hour and plated
to determine colony forming units (CFUs). The mean of 3 replicates ± standard deviation
is plotted, with significant differences determined via an unpaired, one-tailed student’s t
test, ** p < 0.01, *** p < 0.001. LOD = limit of detection.
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3.4 Uptake of 14C-linoleic acid shows less accumulation of
fatty acid over time in strains containing a SNP in cvfA
We have shown that SNPs in cvfA result in a higher tolerance to the presence of linoleic
acid during growth, however we do not know the fate of that linoleic acid. It has been
shown that S. aureus incorporates exogenous fatty acids into its membrane (169, 170).
Therefore, we sought to evaluate whether CS1 is better able to tolerate the accumulation
of this fatty acid in its membrane compared to wild-type, or if there is some other
mechanism occurring, such as reduced entry of the fatty acid or increased efflux. S.
aureus was incubated with 14C-linoleic acid, then applied to filter paper and washed to
allow the detection of linoleic acid accumulated on or in the cells. We observed a
decrease in accumulation of 14C-linoleic acid in CS1 compared to wild-type USA300 and
this difference was exacerbated when USA300 expressed CS1 CvfA from a plasmid
(Figure 6).
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Figure 6. Uptake of 14C-linoleic acid in strains containing a SNP in cvfA. USA300 and
CS1 (A) were grown to stationary phase overnight in TSB while USA300 crosscomplemented with pWT or pCS1 (B) were grown in TSB containing chloramphenicol.
All pre-cultures were diluted to an OD600 of 0.01 in fresh TSB and grown to an OD600 of
approximately 0.5 at which point 0.2 µCi/mL of 14C-linoleic acid was added to the
cultures and 200 µL aliquots were removed at the indicated time points for analysis. The
mean of 4 replicates ± standard deviation is shown, with significant differences
determined via an unpaired, one-tailed student’s t test, * p < 0.05, ** p < 0.01.

56

3.5 Virulence factor production is impaired in CS1
Given that cvfA is an RNase and we aim to identify a mechanism by which the SNPs in
this gene lead to increased FFA resistance, we performed an RNA-sequencing assay
comparing wild-type USA300 and CS1 grown in a sub-inhibitory concentration of
linoleic acid. Hundreds of transcripts were altered in the CS1 strain, and a few select hits
are shown in Table 5. Of particular interest are SAUSA300_1121, SAUSA300_1122
(plsX), SAUSA300_0227 (fadD), and SAUSA300_0229. SAUSA300_1121 is annotated
as a fatty acid biosynthesis transcriptional regulator, while fadD and SAUSA300_0229
(annotated as a putative acyl-coA transferase) may be involved in fatty acid processing.
The plsX gene was recently identified as being involved in the incorporation of
exogenous fatty acids in S. aureus phospholipids (170). Additionally, we identified many
downregulated genes in CS1 that are involved in virulence, including saeR, saeS,
members of the ESAT-6 secretion system, and various hemolysins. Additional virulence
factors were also downregulated, and those shown in Table 5 are a representative
selection.
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Table 5. Summary of RNA sequencing results
Gene number

Gene
name

Foldchange

P-value

SAUSA300_1749

-

13.54

0.009

SAUSA300_1180

-

6.34

0.001

SAUSA300_0268

-

5.38

0.038

SAUSA300_1121

-

3.99

0.003

SAUSA300_1179
SAUSA300_2127

cvfA
-

3.10
3.05

0.005
0.004

SAUSA300_1122

plsX

2.61

0.002

SAUSA300_0227
SAUSA300_0229
SAUSA300_0691
SAUSA300_0690

fadD
saeR
saeS

-2.83
-3.56
-4.70
-4.74

0.012
0.003
0.048
0.033

SAUSA300_0283

essC

-7.28

0.001

SAUSA300_1058
SAUSA300_0304

hla
-

-10.75
-11.49

0.058
0.006

SAUSA300_0409

-

-11.91

0.051

Description
Hypothetical protein, most highly
upregulated gene
Gene located downstream of cvfA and
divergently transcribed
Putative drug transporter
Fatty acid biosynthesis transcriptional
regulator
Phosphodiesterase (RNase Y)
Multidrug resistance efflux pump, SepA
putative glycerol-3-phosphate
acyltransferase
acyl-coA dehydrogenase
putative acyl-CoA transferase, FadX
DNA-binding response regulator
Sensor histidine kinase
Member of the ESAT-6 (type 7) secretion
system
Alpha-hemolysin
Hypothetical membrane protein
Hypothetical protein, most highly
downregulated gene
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Given that several virulence factors were downregulated and that cvfA is known to
process the sae T1 transcript (49), we wanted to further characterize this phenotype. We
began by looking for differences in secreted proteins between wild-type and SNPcontaining S. aureus (Figure 7). Strains were grown in sub-inhibitory linoleic acid for 18
hours and then culture supernatants were harvested and normalized by OD600 before
being subjected to trichloroacetic acid to precipitate proteins. We saw a moderate global
decrease in secreted protein production across the SNP-containing strains, with two
proteins in particular being largely impacted (indicated by arrows). Further analysis
would be required to identify these proteins.
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Figure 7. Secreted protein profiles of USA300 and 5 strains containing SNPs in cvfA.
Stationary phase cultures were normalized by OD600 and centrifuged to pellet bacteria
while the supernatants were subjected to 20% trichloroacetic acid to precipitate secreted
proteins which were visualized by PAGE. Arrows indicate two proteins in wild-type
USA300 that appear to be most affected in the SNP-containing strains.
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Additionally, we streaked single colonies of each mutant as well as the wild-type and
CS1 cross-complemented strains on a blood agar plate to look for differences in
hemolysin production (Figure 8). The cvfA SNPs do not appear to have a significant
impact on hemolysis, despite the observed down-regulation of hla (encoding alpha
hemolysin) from the RNA-sequencing assay. Interestingly, when USA300 is crosscomplemented back with the wild-type cvfA gene (USA300 + pWT), there is a significant
decrease in beta-hemolysis.
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Figure 8. Visualization of the impact of SNPs in cvfA on hemolysin production. Single
colonies of the indicated strains were streaked on 5% sheep’s blood agar and incubated
at 37°C for 16 hours followed by 4°C for 4 hours.
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3.6 Increased survival in vitro in the presence of linoleic
acid does not correlate with increased survival in vivo
Although CS1 appeared to have altered virulence factor expression, this only moderately
extended to virulence factor production, as evidenced in Figure 7 and Figure 8. Also,
given that CS1 is significantly more resistant to linoleic and arachidonic acids in vitro
and that linoleic acid is known to accumulate to high levels in staphylococcal abscesses
(2), we performed a subcutaneous murine skin abscess model comparing abscess
formation between wild-type S. aureus and CS1 (Figure 9). The course of infection was
monitored over 10 days, with the peak of infection, as determined by abscess size,
occurring at 24 hours. There was no statistically significant difference at any time point;
however there was a consistent trend toward decreased virulence in mice infected with
CS1 compared to those infected with wild-type USA300.
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Figure 9. A subcutaneous murine infection model comparing wild-type USA300 and
CS1. 4-7 x 106 colony forming units of S. aureus were injected under the skin of the
flank of each Balb/c mouse. The course of infection over 10 days is shown with
abscess area having been measured by tracing images of the abscess using the computer
program FIJI. The mean of 10 replicates with standard error of the mean is shown.
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3.7 Biochemical characterization of CvfA
3.7.1

Purification of CvfA lacking its transmembrane domain

We have shown that USA300 containing a SNP in cvfA is substantially more resistant to
linoleic and arachidonic acids in vitro. Given that the identified SNPs all localize within
the same region of the gene that codes for a domain with no known function, and also
that the region within CvfA that is responsible for binding other proteins is unknown, we
sought to test whether these SNPs were impacting interactions with protein partners. We
chose to use CvfAL269F as the prototype for the following biochemical assays because
when USA300 was cross-complemented with this SNP-containing gene, it produced a
robust increase in MIC of the two FFAs and also because we have the full genome
sequence for the strain in which this SNP was initially identified (CS1).
To begin protein analysis, we cloned the wild-type and SNP-containing genes into
pET28a for expression in E. coli, using a cloning strategy that resulted in the removal of
the transmembrane domain (Figure 10a). Expression of cvfA was induced with IPTG,
cells were lysed, and following a low speed centrifugation to pellet insoluble material,
CvfA was found in the pellet, indicating that it had likely formed inclusion bodies (Figure
10b). The inclusion bodies were resuspended in 8 M urea and left overnight to solubilise.
Following dilution to 0.8 M urea, the solution was dialysed thereby removing the
remaining urea and allowing the protein to re-fold (Figure 11). This resulted in soluble
CvfA protein that was mostly free of contaminating proteins.
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Figure 10. CvfA was cloned lacking its transmembrane domain and with an N-terminal
histidine tag (A). Upon expression in E. coli (B), CvfA can be visualized at
approximately 58 kDa in induced whole cell lysates. Following lysis and centrifugation,
CvfA was located in the pellet.
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Figure 11. Soluble CvfA was obtained from inclusion bodies via denaturation using
urea. Inclusion bodies were washed and then solubilised in 8 M urea overnight.
Following dilution to 0.8 M urea overnight, all remaining urea was dialysed out of the
solution over two days, resulting in soluble, refolded CvfA.
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Renatured CvfA was used in a bead-based pulldown assay to evaluate protein-protein
interactions. S. aureus whole cell lysate was either added alone to cobalt-coated
magnetic beads as a negative control or first incubated with renatured CvfA. Upon
elution from the beads, samples were visualised for examination of differences in
proteins present. When CvfA was included, it was eluted from the beads; however there
are no other obvious proteins present in this sample (Figure 12). Additionally, we tested
the activity of the protein through a phosphodiesterase assay and found that the protein
was inactive (data not shown), possibly indicating mis-folding of the protein upon
renaturation.
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Figure 12. An in vitro pulldown assay using re-natured wild-type CvfA and S. aureus
whole cell lysate. CvfA was incubated with S. aureus whole cell lysate and added to
cobalt-coated magnetic beads. Following two washes, bound protein was eluted in 1 M
imidazole and visualized using PAGE. As a negative control, whole cell lysate was
incubated with the beads alone and the eluate was visualized.
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3.7.2

Purification of full length CvfA from E. coli membranes

Given the unsuccessful attempts with renatured CvfA lacking its transmembrane domain,
we cloned full length CvfA, including its transmembrane domain, for expression in E.
coli with the assumption that the protein would be present in the membrane, and
detergent extraction would be necessary for its purification (Figure 13a). Postexpression, we first evaluated the solubility of CvfA in various detergents. We identified
that CvfA was solubilised to varying degrees in n-dodecyl β-D-maltoside (DDM), octylβ-D-glucopyranoside (OG) and tween-20. Moreover, when they were used in sequential
fashion, from DDM to OG, to tween-20, the tween-20 fraction contained what appeared
to be pure CvfA (Figure 13b). Unfortunately, however, we found that CvfA present in
this Tween-20-solubilised fraction was incapable of binding to cobalt-coated magnetic
beads (data not shown).
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Figure 13. Full length WT and SNP-containing CvfA genes were cloned with a C-terminal
histidine tag into the pET28a E. coli expression vector (A). Upon expression, CvfA is
visualized at approximately 61 kDa (B). Following lysis, a low speed centrifugation to
pellet insoluble material, and an ultracentrifugation to pellet the membrane, CvfA was
found in the membrane fraction, as predicted. A series of membrane solubilisations using
DDM, OG, and Tween-20 are shown (B). E. coli containing the vector control (pET28a)
was also purified in the same manner (C).
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3.7.3

CvfA characterization

Given that the Tween-20-solubilised protein fraction was unable to interact with cobaltcoated beads, we were unable to perform the pulldown assay as we could not pull the
protein out of solution; however, we were able to perform a phosphodiesterase assay to
look for differences in activity between wild-type and SNP-containing CvfA. The
phosphodiesterase assay used a synthetic substrate, bis-4-nitrophenyl phosphate, and
measured cleavage of this substrate by quantifying the release of product, which absorbs
light at 405 nm. This assay demonstrated that CvfA containing the L269F mutation does
not have altered activity compared to wild-type (Figure 14), with both proteins having a
Km of approximately 3 mM (Table 6).
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Figure 14. Phosphodiesterase activity of Tween-20 solubilised WT or SNP-containing
CvfA and the vector control (pET). Samples were treated with DEPC to inactivate
RNases as a control. Production of 4-nitrophenol (4-NP) by cleavage of bis-4-NPP was
measured by absorbance at 405 nm. The mean ± standard deviation of three technical
replicates is plotted.

Table 6. Km of wild-type and SNP-containing CvfA
CvfA

Km (mM)

CvfAWT

3.09

CvfAL269F

3.08
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We found that both the Tween-20 and OG-solubilised protein fractions were unable to
bind cobalt, however the DDM-solubilised fraction was able to bind, allowing us to
attempt the pulldown assay. Both Tween-20 and DDM are non-ionic detergents and are
thus considered mild detergents not likely to denature proteins. Tween-20 however, is
known to form very large micelles and this may interfere with the ability of CvfA to
interact with other compounds. We employed the DDM-solubilised fraction in a series of
pulldown assays, with the controls consisting of S. aureus lysate incubated with cobaltcoated beads or the protein fraction alone with beads. The protein fraction, both wildtype and SNP-containing, was also incubated with whole cell lysate and applied to the
beads in an attempt to pull out interacting proteins from the lysate. After three washes
with 50 mM imidazole, the samples were eluted in 1 M imidazole to remove any bound
proteins. Unfortunately, there was significant background banding despite the use of 40
mM imidazole during binding. Regardless, there were no easily identifiable bands that
were present in the experimental lanes (1 and 2) that were not also present in the control
lanes (3 and 4) (Figure 15). As such, we have not yet been able to determine whether the
L269F mutation in CvfA impacts protein partner interactions.
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Figure 15. The eluates of 4 pulldown assays were visualized by PAGE. Either SNPcontaining (CvfAL269F) or wild-type CvfA was incubated with S.aureus whole cell lysate
and cobalt-coated magnetic beads were used to pull out CvfA and any interacting protein
partners. Proteins were eluted from the beads using 1 M imidazole. Lysate alone and
CvfA alone were used as negative and positive controls, respectively.
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4

Discussion

In this work, we have selected for S. aureus strains that demonstrate increased resistance
to linoleic and arachidonic acids. Further, we have identified single nucleotide
polymorphisms (SNPs) in the RNase CvfA that are directly linked to this phenotype. The
cvfA gene is the homolog of RNase Y in B. subtilis and the functional equivalent of
RNase E in E. coli. As such, CvfA is thought to act as the central component of the
degradosome, much like RNase Y and RNase E. Our multiple attempts to generate a
cvfA knockout in USA300 met with failure. This, combined with the fact that a
saturating transposon library in USA300, generated out of Nebraska (171), did not
contain an insertion in cvfA, led us to conclude that this is an essential gene in USA300.
It is widely regarded that the CvfA homolog in B. subtilis, RNase Y, is essential.
Interestingly, however, there have been previous reports of knockout cvfA mutants in
different strains of S. aureus (49, 167), and it would be interesting to determine if some
sort of suppressor mutations have occurred in these genetic backgrounds that allow for
the loss of CvfA function.
The reason why the SNPs we have selected for result in a resistance profile that is
specific to linoleic and arachidonic acids is currently unknown. The human body is not
able to synthesize linoleic acid and as such, it is an essential fatty acid. Arachidonic acid
is synthesized from linoleic acid. The structures of these fatty acids are shown in Figure
16 and they are both polyunsaturated fatty acids with double bonds in the cis orientation.
The similarities, however, end there – linoleic acid has an 18 carbon chain length and two
degrees of unsaturation, and arachidonic acid has a 20 carbon chain length and four
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degrees of unsaturation. They are connected in that arachidonic acid is synthesized from
linoleic acid in mammals but how that relates to S. aureus inhibition is unclear. The
specificity toward linoleic and arachidonic acid has been documented in another recent
example of S. aureus FFA resistance (159).
This previous report described a DNA-binding transcriptional regulator and efflux pump
that provides S. aureus with protection against linoleic and arachidonic acids. It is
tempting to speculate that our cvfA mutants are causing the efflux pump, farE, to be
upregulated or that they are altering expression of the transcriptional regulator, farR.
However, we did not identify either of these genes as being differentially regulated in our
RNA-sequencing assay. Additionally, the resistance phenotype described is inducible
whereas resistance in cvfA mutants does not require induction by sub-MIC concentrations
of fatty acid.
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Figure 16. The structures of linoleic and arachidonic acid. Both fatty acids are
polyunsaturated with double bonds in the cis orientation.
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Of particular interest in the RNA-sequencing dataset was the finding that plsX was
upregulated. Recently, a ΔplsX mutant in S. aureus strain RN4220 was reported to be a
fatty acid auxotroph (170). In anticipation of this phenotype, researchers supplemented
the media with exogenous saturated fatty acids in order to obtain this knockout mutant.
The upregulation of plsX in our cvfA SNP mutant, CS1, may be important in processing
these exogenous FFAs for incorporation into S. aureus phospholipid. Additionally,
several putative efflux pumps or drug transporters were also upregulated. Future work to
narrow down an intracellular mechanism would involve creating knockout mutants of
these genes and testing for altered levels of FFA resistance.
Another interesting finding from the RNA-sequencing data was that many virulence
factors were downregulated. CvfA has previously been implicated in S. aureus virulence,
in particular, in the processing of the sae transcript (49, 167). CvfA was shown to cleave
the sae T1 transcript into the predominant T2 transcript, which results in transcript
stabilisation (49). Another group showed that processing by CvfA stabilises some
transcripts by protecting them from degradation by PNPase (172). Of course, this is not
always the case as cvfA is responsible for the destabilisation of other transcripts (49).
Evidently, understanding the full scope of cvfA activity and its regulation of RNA will
require further investigation.
Apart from the regulation of the saePQRS operon, cvfA was shown to be involved in the
regulation of other virulence factors (49) and we have observed a similar role in this
study. In addition to the downregulation of sae transcripts, we found many proteins of
the ESAT-6 secretion system (Ess) to be downregulated. The Ess pathway has been
extensively studied in Mycobacterium tuberculosis and in 2005, homologs to the Ess
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proteins were identified in S. aureus (173). EsxA and EsxB, two members of the Ess, are
exoproteins and mutants defective in their production or secretion were found to be
attenuated in a murine model of infection (173). EssC and EssB are membrane proteins
involved in the translocation of EsxA and EsxB into the extracellular milieu (173, 174).
Interestingly, it was also shown that the proteins of the Ess are negatively regulated by
the saePQRS system and as such, if the sae operon is downregulated, one would expect
transcription of the Ess proteins to be increased (175). However, in our cvfA mutant, we
found both Sae and Ess proteins to be downregulated and as such, CvfA is likely playing
a direct role in the downregulation of the Ess pathway rather than an indirect role through
sae.
While the RNA levels of many virulence factors were altered, we wanted to know if that
extended to the protein levels as well. We visualised levels of secreted virulence factors
in our cvfA SNP mutants and saw a slight global decrease in virulence factor production
along with marked decreases in specific proteins (Figure 7). Further evaluation of these
proteins would be required for their identification. In addition, we visualised the
production of hemolysins by plating strains on a blood agar plate and didn’t find a
significant impact on hemolysis in the SNP-containing strains; however, the wild-type
strain overexpressing wild-type cvfA had a marked reduction in hemolysis (Figure 8).
This strain also showed additional signs of distress, such as slowed growth and increased
pigmentation. This showed us that the increased FFA resistance in cvfA SNP-containing
strains is not simply due to increased expression of the protein and that high levels of
wild-type CvfA negatively impact the bacteria.
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Given the observed downregulation of several virulence factors in the CS1 clone, it was
not surprising to see a trend to decreased virulence in our mouse skin abscess model
(Figure 9). The assay will need to be repeated but also the use of a different in vivo model
may provide more informative results. For example, we could employ a nasal
colonisation model to evaluate FFA survival and a bacteremia model to evaluate
virulence potential.
With a picture of the intracellular and in vivo effects of these cvfA SNPs forming, we
focused on characterizing their biochemical effects. Unfortunately, expression of CvfA
lacking its transmembrane domain resulted in the formation of inclusion bodies and upon
refolding, we were unable to identify any interacting protein partners (Figure 12).
Although the refolded protein was inactive, protein-binding domains are often
unstructured until the interaction forms and thus we thought that the refolded protein
would still form interactions with other proteins. It is possible that the protein re-folded
in such a way that the residues required for interactions are hidden or blocked.
Given our inability to test for protein interactions with the refolded protein, we retained
the transmembrane domain and assessed the effectiveness of various detergents on
solubilising CvfA. Because we were unable to further purify CvfA in the Tween-20solubilised samples due to an inability to interact with cobalt-coated beads, we also
purified the vector control in the same manner to control for background proteins and
used these samples in the phosphodiesterase assay. As expected, we found that this SNP
did not alter the Km of the protein (Table 6) and that the vector control did not have
phosphodiesterase activity, indicating that the activity in our CvfA-containing samples
was indeed coming from CvfA (Figure 14).
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The Km of 3 mM is relatively high indicating low affinity for this substrate; however it is
possible that the detergent may interfere with activity. Tween-20 is known for forming
very large micelles in solution and this may be the reason CvfA will not bind the cobalt
beads in this detergent. It is also possible that the large Tween-20 micelle size impairs
the ability of CvfA to access the substrate in the phosphodiesterase assay. Although the
Km was high, this assay demonstrated that the L269F mutation in CvfA does not impact
protein activity in vitro.
The OG-solubilised protein fraction was also unable to be purified with cobalt beads. We
were able to bind a small amount of CvfA to the beads when the concentration of OG
was decreased from 2% to less than 1%; however this reduction in concentration often
resulted in protein precipitation. This left the DDM-solubilised sample, in which CvfA
was successfully able to bind the cobalt beads for further purification. We performed the
pulldown assay using CvfA and S. aureus whole cell lysates to identify any proteins with
which CvfA interacts; however, we were not able to identify any proteins that were not
also found when lysate or CvfA alone were incubated with the beads (Figure 15).
Attempts to reduce background proteins were made by increasing the amount of
imidazole during binding, however this did not improve the outcome. Unfortunately, we
have not determined whether the identified mutations in CvfA impact protein-protein
interactions.

4.1 Future Directions
There are many additional ways to address the pulldown assay. For example, one of the
protein partners that CvfA is known to interact with could be tagged and the pulldown
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assay performed in the same manner. Enolase is known to interact with CvfA and could
be tagged, purified, and used in a pulldown assay with whole cell lysates containing
either wild-type or mutant CvfA to evaluate the interaction between these proteins.
Theoretically, this may be a simpler approach as enolase and the other proteins of the
degradosome are soluble, cytoplasmic proteins as opposed to the membrane-bound CvfA.
Additionally, the two proteins that CvfA has been shown to interact with, CshA and
Enolase, could be separately purified and binding could be evaluated in vitro. This would
likely be the approach that would give us the most definitive results for these proteins;
however, it is possible that CvfA interacts with other proteins and this approach would
preclude their identification. Finally, CvfA could be overexpressed directly in S. aureus
cells with a tag to allow its purification. With the addition of a crosslinking reagent, we
could pull out CvfA and any interacting partners directly from S. aureus. This approach
would have the advantage of being performed directly within the native environment in
which these proteins would normally interact and would therefore produce the most
applicable results.
Apart from the pulldown assay, it would be interesting to purify the other SNP-containing
proteins and determine their impact on protein activity. CvfA from CS1 (CvfAL269F) was
found to have no impact on phosphodiesterase activity, however, SNPs in cvfA from CS2
and CS4 cluster close to the catalytic domain of the protein. USA300 + pCS2 and
USA300 + pCS4 also have a lower linoleic acid MIC compared to the other crosscomplemented strains. This observation led us to question whether the five SNPs are all
impacting the same aspect of protein function. It is possible that the SNPs in CS1, CS3,
and CS5 may impact protein-protein interactions or RNA binding while the SNPs in CS2
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and CS4 could have an impact on protein activity. CvfA from these strains would be
cloned and purified from E. coli membranes and phosphodiesterase activity tested, as
described for CS1.
Moreover, to gain a more complete understanding of the impact of the amino acid
changes, we could mutate the identified amino acids to alanine and test for increased fatty
acid resistance. This would help us determine whether it is the loss of amino acid side
chain resulting in increased resistance or the gain of a specific side chain. We could also
select for additional resistance-conferring SNPs in this gene and determine whether the
mutations occur randomly throughout this uncharacterized domain or in a select few
positions.
In addition to the characterization of the biochemical effect of the SNPs, another priority
would be the elucidation of their intracellular impact. Following confirmation of RNAseq results, a knockout mutant of plsX could be created and evaluated for its impact on
linoleic acid resistance. If plsX is found to have an effect, an in vitro binding assay with
purified wild-type and SNP-containing CvfA and plsX RNA would allow the
determination of whether the SNP is impacting cleavage/degradation of plsX.
Finally, we are going to determine the fatty acid phospholipid profiles of USA300 and
CS1 to look for changes in the composition of the membrane fatty acids. It has
previously been shown that when S. aureus is grown in the presence of oleic acid, a nontoxic fatty acid, oleic acid is elongated by two carbons through bacterial type 2 fatty acid
synthesis machinery and incorporated into the membrane (151). If the same thing occurs
when S. aureus is grown in linoleic acid, the result would be eicosadienoic acid, a rare
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polyunsaturated fatty acid, being incorporated into the membrane (176). The impact of
this is unknown and could represent a potential mechanism of toxicity of linoleic acid in
USA300. If there are differences in phospholipid fatty acid composition between
USA300 and CS1, this may also implicate plsX or related proteins involved in the
incorporation of exogenous fatty acids into the membrane as being involved in the
increased fatty acid resistance of CS1.

4.2 Conclusion
Overall, we have described the characterization of S. aureus mutants that are highly
resistant to linoleic and arachidonic acids, but not other unsaturated FFAs. These
mutants have SNPs in cvfA, all within a narrow region of the gene that codes for a
domain with unknown function. The cvfA gene encodes an RNase that is a central
component of the degradosome within S. aureus and participates in the complex
regulation of many different genes, particularly those involved in virulence. The protein
is anchored in the membrane resulting in difficulties with protein purification; however
we have successfully showed that the protein encoding a SNP variant, CvfAL269F, does
not have altered activity compared to wild-type. Additional studies are required to
determine whether the SNPs impact protein-protein interactions or any other aspect of
protein function, such as RNA-binding.
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